1. Pink Sheet
  2. >>Geography
  3. >>Europe

EMA Explains How To Use Electronic Devices For Direct Trial Data Capture

 
• By Vibha Sharma

In response to a proposal by Novartis, the European Medicines Agency has outlined the broad characteristics of electronic systems used for directly capturing clinical trial data by investigator staff.

Clinical trial
EMA Outlines Ideal Characteristics Of Systems For Direct Data Entry • Source: Shutterstock

The European Medicines Agency has issued guidance on the regulatory acceptability of using apps or electronic devices to directly capture clinical trial source data at the point of care by investigator site staff.

The guideline explains how some of the data captured through apps or electronic devices such as tablets can be identified as “case report form” (CRF) data for clinical trial purposes....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.